But what I will mention is that we’ve had a remarkable response on both fronts, both from the surgical community on our TCAR system, as well as the EFS within the neuro community. We think that the neuro community has been underserved by carotid focus, and we’re looking forward to having both those added to our tool set for our foundational CAS system.
Operator: The next question comes Ben Haynor of Alliance Global Partners.
Benjamin Haynor: First off for me, congrats on the National Coverage Determination. But regarding that, I guess what’s your view on the expansion in terms of numbers? If the addressable patient population was x and now it’s x+y, what are those x’s and y’s?
Marvin Slosman: I think some of that is certainly to be determined. Right? What we know is that there’s a tremendous amount of energy behind this decision by CMS. What we think about over the next several years is a shift from surgery. First, let’s call it, a 70% or 80% surgery first to a 70% or 80% endovascular stenting first. How that plays out in terms of what percent of that market is CAS procedures versus TCAR is still to be determined. We know that both are very viable options, which is why we invested in both of those tool sets in order to give us the broadest range within carotid revascularization. It’s interesting that, at the conferences, some of the discussion now is becoming, is that a stentable lesion, which you’ve never heard before, as opposed to just assuming the default on – endarterectomy or surgery being sort of the baseline.
So the CMS coverage really opens up the market opportunity for us, and I think fits perfectly to our strategy, which is to make sure that we’ve got the full coverage of tool set regardless of which access is used for the best implant. So I think we’re in good shape there and feel good about the transition. The question of timing and percentage is still to be determined.
Benjamin Haynor: You mentioned the discussion that’s going on at these conferences, obviously at VIVA. Any additional color there? Any surprises on the discussions where, is that a stentable lesion, things that maybe you hadn’t thought of or just anything surprising there?
Marvin Slosman: Well, I think what’s been most surprising is just the remarkable results that we presented. Let’s think about the unprecedented nature of being able to deliver, even in 30 days, a sub 1% complication rate is really unprecedented. So I think it goes beyond just, will stents become standard of care? It’s really a question of this is a unique platform that, frankly, has never been seen before in terms of these outcomes. Now, I will mention also that this validates our previous experience in the 1,850 patients we’ve studied at about 1.2% rate. So I think it’s – listen, it’s a combination of a lot more discussion, momentum, and transition. But we like being in a position of being able to lead that way by talking about clinical outcomes and procedural opportunities that really result in best implant and best outcomes because that’s going to be the trend, right?
There will be more momentum in CAS and in TCAR, but I think, ultimately, the decision points will be what’s best for the patient and how do those outcomes translate from the implant itself and not just the procedure.
Operator: Thank you. Ladies and gentlemen, we have reached the end of our question-and-answer session. I will now hand over to Mr. Marvin Slosman for closing remarks.
Marvin Slosman: I would like to thank everyone for joining the call today. We look forward to a strong finish in 2023 and advancing our plans of growth toward great execution for 2023 and beyond. Thank you.
Operator: Thank you, sir. Ladies and gentlemen, that concludes today’s event. Thank you for attending and you may now disconnect your lines.
